All TKIs approved for CML treatment share kinase inhibition activity against BCR-ABL; however, they differ in their kinase inhibition profiles (the so-called “off-target effect”), and some are vascular biology-related kinases [9]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.